IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+11.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.07B
AUM Growth
+$1.07B
(+19%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
9.88%
Top 10 Holdings %
Top 10 Hldgs %
45.5%
Holding
98
New
18
Increased
24
Reduced
16
Closed
24
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$26.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$26.3M |
| 3 |
Cardinal Health
CAH
|
$23.5M |
| 4 |
Eli Lilly
LLY
|
$19.5M |
| 5 |
Charles River Laboratories
CRL
|
$17.4M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$19.6M |
| 2 |
Ascendis Pharma
ASND
|
$15.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 4 |
Krystal Biotech
KRYS
|
$10.8M |
| 5 |
Boston Scientific
BSX
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
GE HealthCare
GEHC
$33B
| $14.8M | 1.36% |
200,000
+50,000
| +33% | +$3.7M |
|
27
AstraZeneca
AZN
$255B
| $14M | 1.28% |
+200,000
| New | +$14M |
|
28
Edgewise Therapeutics
EWTX
$1.54B
| $13.1M | 1.2% |
1,000,000
+325,000
| +48% | +$4.26M |
|
29
Oric Pharmaceuticals
ORIC
$1.03B
| $12.7M | 1.16% |
+1,250,000
| New | +$12.7M |
|
30
Revolution Medicines
RVMD
$7.43B
| $12M | 1.09% |
325,000
+75,000
| +30% | +$2.76M |
|
31
89bio
ETNB
$1.37B
| $10.3M | 0.94% |
1,050,000
| – | – |
|
32
Penumbra
PEN
$10.5B
| $10.3M | 0.94% |
40,000
+5,000
| +14% | +$1.28M |
|
33
MoonLake Immunotherapeutics
MLTX
$3.78B
| $9.44M | 0.86% |
200,000
| – | – |
|
34
Inspire Medical Systems
INSP
$2.53B
| $9.08M | 0.83% |
70,000
+5,000
| +8% | +$649K |
|
35
Acadia Healthcare
ACHC
$2.15B
| $9.08M | 0.83% |
400,000
+150,000
| +60% | +$3.4M |
|
36
Beam Therapeutics
BEAM
$1.9B
| $8.51M | 0.78% |
+500,000
| New | +$8.51M |
|
37
Hologic
HOLX
$14.7B
| $8.15M | 0.75% |
+125,000
| New | +$8.15M |
|
38
Tarsus Pharmaceuticals
TARS
$2.44B
| $8.1M | 0.74% |
200,000
| – | – |
|
39
Rezolute
RZLT
$630M
| $8.03M | 0.74% |
1,800,000
+1,300,000
| +260% | +$5.8M |
|
40
Rhythm Pharmaceuticals
RYTM
$6.75B
| $7.58M | 0.69% |
+120,000
| New | +$7.58M |
|
41
Baxter International
BAX
$12.1B
| $7.57M | 0.69% |
250,000
-250,000
| -50% | -$7.57M |
|
42
AbbVie
ABBV
$374B
| $7.42M | 0.68% |
40,000
-20,000
| -33% | -$3.71M |
|
43
McKesson
MCK
$85.9B
| $7.33M | 0.67% |
10,000
-2,000
| -17% | -$1.47M |
|
44
Roivant Sciences
ROIV
$8.6B
| $6.76M | 0.62% |
600,000
| – | – |
|
45
iRhythm Technologies
IRTC
$5.67B
| $6.16M | 0.56% |
+40,000
| New | +$6.16M |
|
46
Agilent Technologies
A
$35.5B
| $5.9M | 0.54% |
+50,000
| New | +$5.9M |
|
47
Regenxbio
RGNX
$498M
| $5.75M | 0.53% |
700,000
-225,000
| -24% | -$1.85M |
|
|
VRNA
48
Verona Pharma
VRNA
$9.18B
| $5.67M | 0.52% |
60,000
-55,000
| -48% | -$5.2M |
|
49
Alignment Healthcare
ALHC
$3.23B
| $5.6M | 0.51% |
400,000
+200,000
| +100% | +$2.8M |
|
|
ATYR
50
aTyr Pharma
ATYR
$560M
| $5.32M | 0.49% |
1,050,000
+350,000
| +50% | +$1.77M |
|